Imaging Studies in Corticobasal Syndrome
Neuroinflammation, White Matter Integrity, AD Biomarkers and Pathology in Corticobasal Syndrome
Jennifer Whitwell
80 participants
Jun 25, 2025
OBSERVATIONAL
Conditions
Summary
The primary goal of this study is to investigate inflammation and white matter damage in corticobasal syndrome and determine whether these processes are related to each other. The investigator's will address our goal by using neuroimaging and blood plasma biomarkers, as well as molecular pathology.
Eligibility
Inclusion Criteria2
- Age 18 years or older
- Meet possible or probable CBS criteria
Exclusion Criteria7
- Subjects will be excluded if MRI is contraindicated (due to implanted device, severe claustrophobia, etc)
- Subjects will be excluded if they have a concurrent illnesses or structural abnormality that could account for the CBS syndrome
- Subjects will be excluded if they have a mutation in the progranulin gene
- Subjects will excluded if they have received anti-Aβ therapy
- Women who are pregnant will be excluded
- Subjects will be excluded if they are actively taking daily anti-inflammatory medications (NSAIDs, corticosteriods, etc)
- Subjects will be excluded if they have generalized inflammatory condition and treatment with immunosuppressive, corticoid/glucocorticoid, steroidal or non-steroidal anti-inflammatory medication within 2 weeks of scanning
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
PET scan looking for inflammation
PET scan looking for amyloid protein
Pet scan looking for Tau protein
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07000851